Lilly Submits Cymbalta(R) Supplemental New Drug Application For Chronic Pain To U.S. Food And Drug Administration
Eli Lilly and Company (NYSE: LLY) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a new indication for Cymbalta(R) (duloxetine HCl) for the management of chronic pain, the company announced.
More: continued here
Filed under: Pain / Anesthetics on June 1st, 2008